De Domenico Ivana, Ward Diane McVey, Kaplan Jerry
Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
Blood. 2009 Nov 12;114(20):4546-51. doi: 10.1182/blood-2009-05-224188. Epub 2009 Aug 11.
Deferoxamine (DFO) is a high-affinity Fe (III) chelator produced by Streptomyces pilosus. DFO is used clinically to remove iron from patients with iron overload disorders. Orally administered DFO cannot be absorbed, and therefore it must be injected. Here we show that DFO induces ferritin degradation in lysosomes through induction of autophagy. DFO-treated cells show cytosolic accumulation of LC3B, a critical protein involved in autophagosomal-lysosomal degradation. Treatment of cells with the oral iron chelators deferriprone and desferasirox did not show accumulation of LC3B, and degradation of ferritin occurred through the proteasome. Incubation of DFO-treated cells with 3-methyladenine, an autophagy inhibitor, resulted in degradation of ferritin by the proteasome. These results indicate that ferritin degradation occurs by 2 routes: a DFO-induced entry of ferritin into lysosomes and a cytosolic route in which iron is extracted from ferritin before degradation by the proteasome.
去铁胺(DFO)是由毛链霉菌产生的一种高亲和力铁(III)螯合剂。DFO在临床上用于治疗铁过载疾病患者以去除体内的铁。口服DFO无法被吸收,因此必须进行注射。在此我们表明,DFO通过诱导自噬促使溶酶体中的铁蛋白降解。经DFO处理的细胞显示出LC3B在胞质中的积累,LC3B是一种参与自噬体-溶酶体降解的关键蛋白。用口服铁螯合剂去铁酮和地拉罗司处理细胞未显示出LC3B的积累,且铁蛋白的降解是通过蛋白酶体进行的。用自噬抑制剂3-甲基腺嘌呤处理经DFO处理的细胞,导致铁蛋白通过蛋白酶体降解。这些结果表明,铁蛋白降解通过两条途径发生:DFO诱导铁蛋白进入溶酶体,以及一条胞质途径,即在蛋白酶体降解之前从铁蛋白中提取铁。